Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ADX48621 in the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease.

Trial Profile

Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ADX48621 in the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2016

At a glance

  • Drugs Dipraglurant (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Addex Therapeutics
  • Most Recent Events

    • 23 May 2016 Results published in the Movement Disorders
    • 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
    • 13 Jul 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top